Quarterly ResultAug 12, 2026, 07:08 AM
Acumen Q2 Net Loss $32.7M, EPS $(0.45); Pipeline Advances
AI Summary
Acumen Pharmaceuticals reported a Q2 2026 net loss of $32.7 million, or $(0.45) per share, an improvement from a net loss of $41.0 million, or $(0.68) per share, in Q2 2025. The company's cash, cash equivalents, and marketable securities stood at $110.2 million as of June 30, 2026, expected to fund operations into early 2027. Key business highlights include anticipated topline results for the ALTITUDE-AD Phase 2 study in late 2026 and targeting a mid-2027 IND filing for a lead candidate in its Enhanced Brain Delivery™ program.
Key Highlights
- Q2 2026 net loss was $32.7 million, down from $41.0 million in Q2 2025.
- Q2 2026 net loss per share was $(0.45), an improvement from $(0.68) in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $110.2 million as of June 30, 2026.
- R&D expenses decreased to $27.8 million in Q2 2026 from $37.1 million in Q2 2025.
- Loss from operations improved to $32.6 million in Q2 2026 from $41.8 million in Q2 2025.
- Topline results for ALTITUDE-AD Phase 2 study expected in late 2026.
- Lead EBD program candidate IND filing targeted for mid-2027.
Price Impact
More from ABOS